

S1 Table. Comparison of patient characteristics between MRI- and CT-based IGBT

Characteristic	MRI-based IGBT (n=30)	CT-based IGBT (n=20)	p-value
Age at diagnosis (yr)	49 (31-70)	50.5 (31-80)	0.626
FIGO stage			0.088
II	3 (10.0)	5 (25.0)	
III	26 (86.7)	12 (60.0)	
IV	1 (3.3)	3 (15.0)	
Pathology			0.432
Squamous cell carcinoma	25 (83.3)	15 (75.0)	
Adenocarcinoma	5 (16.7)	4 (20.0)	
Others	0	1 (5.0)	
Parametrial invasion			0.499
Yes	26 (86.7)	15 (75.0)	
No	4 (13.3)	5 (25.0)	
Pelvic lymph node metastasis			0.251
Yes	5 (16.7)	7 (35.)	
No	25 (83.3)	13 (65.0%)	
Paraaortic lymph node metastasis			0.279
Yes	6 (20.0)	1 (5.0)	
No	24 (80.0)	19 (95.0)	
Pelvic organ invasion			0.715
Yes	1 (3.3)	2 (10.0)	
No	29 (96.7)	18 (90.0)	
Distant metastasis			0.837
Yes	0	1 (5.0)	
No	30 (100)	19 (95.0)	
Initial tumor size (cm)	5.8 (2.4-9.6)	5.1 (3.3-7.1)	0.054
Brachytherapy dose prescription (Gy)	30 (25-30)	30 (26-30)	0.090
Brachytherapy fractions			0.002
4	0	6 (30.0)	
5	30 (100)	13 (65.0)	
6	0	1 (5.0)	
EBRT technique			0.929
IMRT	27 (90.0)	17 (85.0)	
3D-CRT	3 (10.0)	3 (15.0)	
EBRT pelvic dose fractionation			0.302
45.0 Gy/25 fractions	30 (100)	18 (90.0)	
50.4 Gy/28 fractions	0	2 (10.0)	
EBRT nodal boost			0.130
Yes	25 (83.3)	12 (60.0)	
No	5 (16.7)	8 (40.0)	
EBRT parametrial boost			1.000
Yes	16 (53.3)	10 (50.0)	
No	14 (46.7)	10 (50.0)	
EBRT cervical tumor boost			0.395
Yes	3 (10.0)	20 (100)	
No	27 (90.0)	0	
Duration of radiation therapy (day)	54 (47-63)	55 (49-61)	0.466
Concurrent chemotherapy regimen			1.000
Weekly cisplatin	24 (80.0)	16 (80.0)	
Tri-weekly cisplatin	6 (20.0)	4 (20.0)	
Pelvic lymph node surgery			0.732
Dissection	3 (10.0)	3 (15.0)	

Sampling	3 (10.0)	1 (5.0)	
None	24 (80.0)	16 (80.0)	
Para-aortic lymph node surgery			0.171
Dissection	0	1 (5.0)	
Sampling	3 (10.0)	0	
None	27 (90.0)	19 (95.0)	
Positive pathological lymph node			0.577
Yes	3 (10.0)	3 (15.0)	
No	4 (13.3)	1 (5.0)	
Not observed	23 (76.7)	16 (80.0)	
Additional treatment after brachytherapy ^{a)}			0.302
Yes	0	2 (10.0)	
No	30 (100)	18 (90.0)	

Values are presented as median (range) or number (%). 3D-CRT, 3-dimensional conformal radiation therapy; EBRT, external beam radiotherapy; FIGO, International Federation of Gynecology and Obstetrics; IGBT, image-guided brachytherapy; IMRT, intensity-modulated radiation therapy.

^{a)}Consolidative immunotherapy administered by other prospective trial was excluded.